Xing Liu
5 Papers
Xing Liu is an academic researcher. The author has contributed to research in topics: Medicine & Chemistry. The author has an hindex of 1, co-authored 4 publications.
Chat about Author
Papers
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Fei Tong,Jixing Zhao,Zijing Fang,Xiaoteng Cui,Dong-yuan Su,Xing Liu,Junhu Zhou,Guangbin Wang,Zhijun Qiu,Shi-zhong Liu,Jun-qi Fu,Chunsheng Kang,Jiacheng Wang,Qixue Wang +13 more
TL;DR: In this article , a small molecule, EPIC-1027, was used to stabilize EGFRvIII in glioblastoma (GBM) using CRISPR-Cas9 library screening.
20
Integrated single‐cell and spatial transcriptomic profiling reveals higher intratumour heterogeneity and epithelial–fibroblast interactions in recurrent bladder cancer
Zhenjun Shi,Zhuo Sun,Zuo-bin Zhu,Xing Liu,Jun-Zhi Chen,Lin Hao,Jie-Fei Zhu,Kun Pang,Di Wu,Yang Dong,Yufei Liu,Wei-hua Chen,Qing Liang,Shichao Zhuo,Cong Han +14 more
TL;DR: An enhanced interplay between CAFs and malignant cells in bladder recurrent tumours is observed, and a marked increase in activity between cancer‐associated fibroblasts andmalignant cells, as well as other immune cells in recurrent tumour tissues.
9
Targeted delivery of nuclear targeting probe for bladder cancer using cyclic pentapeptide c(RGDfK) and acridine orange
Jia-xin Qin,Qing Liang,Guangyue Wang,Lin Hao,Xing Liu,Xinlei Wang,Zhengxiang Hu,Gaochuan Fang,Liang Xue,Yan Zhao,Ruiqiang Li,Qian Lv,Jiling Wen,Guosheng Yang,Conghui Han,Zhenduo Shi +15 more
TL;DR: The AO-(cRGDfK)2 probe exhibited nuclear-specific accumulation in BCa cells without cytotoxicity, which provides an innovative alternative to improve anticancer therapy for BCa.
3
Co-delivery of siAPE1 and melatonin by 125I-loaded PSMA-targeted nanoparticles for the treatment of prostate cancer
Zhenjun Shi,Kun Pang,Yang Liu,Lin Hao,Yang Dong,Bingzheng Dong,Xing Liu,Gaochuan Fang,Guangrong Wang,Jia-xin Qin +9 more
TL;DR: In this paper , the authors evaluated the therapeutic efficiency of self-assembled and prostate-specific membrane antigen (PSMA)-targeted nanocarrier loading 125I radioactive particles and encapsulating siRNA targeting APE1 and melatonin for prostate cancer (PCa) growth.
Primary papillary epithelial tumor of the sella and posterior pituitary tumor show similar (epi)genetic features constitute a single neurooncological entity.
Jing Feng,Zejun Duan,Kun Yao,Qiu-Ping Gui,Xing Liu,Xingfu Wang,Zunguo Du,Liwei Shao,Benyan Zhang,Shanshan Cai,Mingwang Zhu,Zhong Ma,Ze-Liang Hu,Xiaolong Fan,Qi Xueling +14 more
TL;DR: In this article , a comprehensive clinical, histopathologic and molecular assessment of 5 primary papillary epithelial tumor of the sella (PPETS) cases was performed and the results indicated that PPETS and posterior pituitary tumor (PPT) may constitute a single neurooncological entity.